BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morotti M, Becker CM, Menada MV, Ferrero S. Targeting tyrosine-kinases in ovarian cancer. Expert Opin Investig Drugs 2013;22:1265-79. [PMID: 23815710 DOI: 10.1517/13543784.2013.816282] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Tozzi R, Casarin J, Baysal A, Pinelli C, Matak L, Ghanbarzadeh N, Alazzam M, Garruto-Campanile R, Majd HS, Kilic Y, Morotti M. Morbidity of multiple bowel resection compared to single bowel resection after debulking surgery for ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2019;240:215-9. [PMID: 31326636 DOI: 10.1016/j.ejogrb.2019.07.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Sato K, Hanaoka H, Watanabe R, Nakajima T, Choyke PL, Kobayashi H. Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer. Mol Cancer Ther 2015;14:141-50. [PMID: 25416790 DOI: 10.1158/1535-7163.MCT-14-0658] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.0] [Reference Citation Analysis]
3 So W, Cheng J, Liu Y, Xu C, Zhao J, Chang VTW, Leung PCK. Sprouty4 mediates amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells. Tumor Biol 2016;37:9197-207. [DOI: 10.1007/s13277-016-4790-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
4 Pinelli C, Morotti M, Casarin J, Tozzi R, Ghezzi F, Mavroeidis VK, Alazzam M, Soleymani Majd H. Interval Debulking Surgery for Advanced Ovarian Cancer in Elderly Patients (≥70 y): Does the Age Matter? J Invest Surg 2021;34:1023-30. [PMID: 32148117 DOI: 10.1080/08941939.2020.1733146] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Liu Z, Du R, Long J, Guo K, Ge C, Bi S, Xu Y. microRNA-218 promotes gemcitabine sensitivity in human pancreatic cancer cells by regulating HMGB1 expression. Chin J Cancer Res 2015;27:267-78. [PMID: 26157323 DOI: 10.3978/j.issn.1000-9604.2015.04.06] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
6 Davidson B, Tropé CG. Ovarian cancer: diagnostic, biological and prognostic aspects. Womens Health (Lond) 2014;10:519-33. [PMID: 25335543 DOI: 10.2217/whe.14.37] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
7 Marchetti C, Palaia I, De Felice F, Musella A, Donfracesco C, Vertechy L, Romito A, Piacenti I, Musio D, Muzii L, Tombolini V, Benedetti Panici P. Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients. Cancer Treat Rev 2016;42:41-6. [PMID: 26559739 DOI: 10.1016/j.ctrv.2015.10.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
8 Morotti M, Dass PH, Harris AL, Lord S. Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients. Eur J Drug Metab Pharmacokinet 2018;43:137-53. [PMID: 29019020 DOI: 10.1007/s13318-017-0442-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Cao W, Yang W, Fan R, Li H, Jiang J, Geng M, Jin Y, Wu Y. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol. 2014;35:1287-1295. [PMID: 24068565 DOI: 10.1007/s13277-013-1171-7] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 5.6] [Reference Citation Analysis]
10 Liu H, Li P, Li B, Sun P, Zhang J, Wang B, Jia B. RKIP promotes cisplatin-induced gastric cancer cell death through NF-κB/Snail pathway. Tumour Biol 2015;36:1445-53. [PMID: 25547433 DOI: 10.1007/s13277-014-2496-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Pinelli C, Morotti M, Casarin J, Tozzi R, Alazzam M, Mavroeidis VK, Soleymani Majd H. The Feasibility of Cardiophrenic Lymphnode Assessment and Removal in Patients Requiring Diaphragmatic Resection During Interval Debulking Surgery for Ovarian Cancer. J Invest Surg 2021;34:756-62. [PMID: 31809609 DOI: 10.1080/08941939.2019.1690077] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Davidson B, Trope CG, Reich R. The role of the tumor stroma in ovarian cancer. Front Oncol 2014;4:104. [PMID: 24860785 DOI: 10.3389/fonc.2014.00104] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
13 Song G, Chen L, Zhang B, Song Q, Yu Y, Moore C, Wang TL, Shih IM, Zhang H, Chan DW, Zhang Z, Zhu H. Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors. Mol Cell Proteomics 2019;18:448-60. [PMID: 30523211 DOI: 10.1074/mcp.RA118.000851] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
14 Zhou C, Chen L, Chen R, Xu F, Huang Z, Huang R, Wang W, Xu Q. miR-4486 enhances cisplatin sensitivity of gastric cancer cells by restraining the JAK3/STAT3 signalling pathway. J Chemother 2021;:1-10. [PMID: 34167436 DOI: 10.1080/1120009X.2021.1936957] [Reference Citation Analysis]
15 Evangelisti G, Barra F, Moioli M, Sala P, Stigliani S, Gustavino C, Costantini S, Ferrero S. Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer. Expert Opin Investig Drugs 2020;29:779-92. [PMID: 32539469 DOI: 10.1080/13543784.2020.1783238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Matias-Guiu X, Davidson B. Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch 2014;464:315-31. [PMID: 24504546 DOI: 10.1007/s00428-013-1509-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
17 Fu LJ, Wang B. Investigation of the hub genes and related mechanism in ovarian cancer via bioinformatics analysis. J Ovarian Res 2013;6:92. [PMID: 24341673 DOI: 10.1186/1757-2215-6-92] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
18 Ntanasis-Stathopoulos I, Fotopoulos G, Tzanninis IG, Kotteas EA. The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review. Cancer Invest 2016;34:313-39. [PMID: 27486869 DOI: 10.1080/07357907.2016.1206117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]